Want to see IGC full AI Analyst Report?
IGC Stock Chart & Stats
$0.30
>-$0.01(-0.38%)
At close: 4:00 PM EDT
$0.30
>-$0.01(-0.38%)
Day’s Range― - ―
52-Week Range$0.24 - $0.45
Previous Close$0.27
Volume109.78K
Average Volume (3M)622.29K
Market Cap
$25.33M
Enterprise Value$26.51M
Total Cash (Recent Filing)$354.00K
Total Debt (Recent Filing)$1.08M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Nov 18, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding103,384,010
10 Day Avg. Volume717,761
30 Day Avg. Volume622,286
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.08
Price to Sales (P/S)21.08
P/FCF Ratio-4.09
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue23.60
Enterprise Value/Gross Profit107.75
Enterprise Value/Ebitda-3.57
Forecast
1Y Price Target
$6.00Price Target Upside1900.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$1.10M
Bulls Say, Bears Say
Bulls Say
Modest LeverageModest leverage reduces near-term balance-sheet strain and gives IGC more flexibility than highly indebted peers. Lower debt exposure can help preserve strategic options while the company develops its pipeline, although continuing losses could still pressure equity over time.
Financing AccessDebt conversion directly reduces liabilities, while the extended loan facility preserves access to financing for ongoing development activities. Together, these actions support liquidity and balance-sheet flexibility, though they also demonstrate that external capital remains important to the business.
Positive Gross MarginA positive gross margin indicates that the company retains some economic value from its current revenue base, while less severe losses than in earlier years suggest partial progress in operating performance. Sustaining or improving this trend could support future development as revenue expands.
Bears Say
Declining Revenue BaseVery small and declining revenue provides little internal funding for clinical development and leaves the company dependent on future pipeline success. Without sustained commercial growth, IGC has limited ability to absorb fixed costs, finance trials, or build a durable operating platform.
Severe UnprofitabilityThe extreme loss profile shows that the current cost structure is far out of proportion to revenue, making profitability highly dependent on successful development and eventual commercialization. Continued losses can consume equity and increase the need for financing before products generate meaningful sales.
Persistent Cash BurnPersistent negative operating and free cash flow limits the company’s ability to fund activities internally and increases reliance on debt, equity, or strategic transactions. The sharp TTM free-cash-flow deterioration adds pressure to preserve liquidity while advancing clinical programs.
IGC Pharma News
IGC FAQ
What was IGC Pharma’s price range in the past 12 months?
IGC Pharma lowest stock price was $0.23 and its highest was $0.45 in the past 12 months.
What is IGC Pharma’s market cap?
IGC Pharma’s market cap is $25.33M.
When is IGC Pharma’s upcoming earnings report date?
IGC Pharma’s upcoming earnings report date is Nov 18, 2026 which is in 28 days.
How were IGC Pharma’s earnings last quarter?
IGC Pharma released its earnings results on Jun 15, 2026. The company reported -$0.02 earnings per share for the quarter.
Is IGC Pharma overvalued?
According to Wall Street analysts IGC Pharma’s price is currently Undervalued.
Does IGC Pharma pay dividends?
IGC Pharma does not currently pay dividends.
What is IGC Pharma’s EPS estimate?
IGC Pharma’s EPS estimate is -0.02.
How many shares outstanding does IGC Pharma have?
IGC Pharma has 103,384,010 shares outstanding.
What happened to IGC Pharma’s price movement after its last earnings report?
IGC Pharma reported an EPS of -$0.02 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of IGC Pharma?
Currently, no hedge funds are holding shares in IGC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IGC Pharma
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
IGC Stock 12 Month Forecast
Average Price Target
$6.00
▲(1900.00% Upside)
Technical Analysis
Ownership Overview
12.31% Insiders
1.32% Mutual Funds
0.07% Other Institutional Investors
84.61% Public Companies and
Individual Investors